Clinical Trial

Dose Optimization Study of Idelalisib in Follicular Lymphoma

Study Description

Dose Optimization Study of Idelalisib in Follicular Lymphoma

The primary objective of this study is to establish a safe and effective dosing regimen of idelalisib in participants with relapsed or refractory follicular lymphoma (FL) who have no other therapeutic options.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - Idelalisib

Idelalisib tablet administered orally

Additional Information

Official Study Title

Dose Optimization Study of Idelalisib in Follicular Lymphoma

Clinical Trial ID

NCT02536300

ParticipAid ID

neg6Dd